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Introduction Inflammatory bowel diseases (IBD) are chronic intestinal inflammatory disorders. To 
date, the expression of metallothioneins (MTs), multifunctional acute stress proteins, in IBD patients 
and their role during intestinal inflammation is indistinct. Our aim was to address a functional role to 
the presence or absence of MTs during gut inflammation. 
Materials and Methods Metallothionein knockout (MT
-/-
), transgenic (MT
+/+
) and wild type mice (WT) 
were subjected to 4% Dextran Sulfate Sodium (DSS) for 7 days followed by 7 days of normal drinking 
water. Body weight and mortality were recorded daily. Anti-MT antibody (or isotype control) treatment 
was used in a curative setting to study the effect of exogenous blocking of MTs during experimental 
colitis. Inflammatory response and serum zinc levels were assessed. 
Results Mice lacking MT showed a significant higher survival rate compared to MT
+/+
 mice (p<0.05; 
90% survival for MT
-/-
 mice versus 52% for MT
+/+
 mice). During the recovery period, histological 
inflammation, neutrophil infiltration and epithelial proliferation were in favor of MT
-/-
 mice (p<0.05). 
Baseline serum zinc levels were significantly lower in the MT
+/+
 mice (p<0.05). Zinc levels decreased 
during the course of colitis in all three groups but this was less pronounced in the MT
-/-
 mice. DSS 
exposed mice treated with the anti-MT antibody tended to lose less body weight and scored better for 
histological inflammation compared to control treated mice at day 10. Inflammatory cell infiltrate, 
represented as macrophages, was significantly lower in the anti-MT treated mice compared to control 
mice (p<0.05). Improved recovery of anti-MT treated mice was modulated by an enhanced hypoxic 
adaptive response with significant higher levels of the beneficial hypoxia-inducible factor 1 alpha and 
an increased vascularization compared to the control group (p<0.05). 
Conclusion A low MT profile during colitis was associated with enhanced recovery and prolonged 
survival of DSS-induced colitis. Targeting extracellular metallothioneins using anti-MT antibody 
confirmed the beneficial properties of a low MT profile during recovery of colitis and allows 
extrapolation to future therapeutic opportunities for patients suffering from IBD. 
 
